Abbvie Inc. Common Stock (ABBV) 70.01 $ABBV Sea
Post# of 273254
Posted On: 08/01/2015 2:40:47 AM
Abbvie Inc. Common Stock (ABBV) 70.01 $ABBV
Seattle Genetics (SGEN) Loss Widens in Q2, Ups 2015 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 31, 2:35PM CDT
Seattle Genetics (SGEN) reported a loss of 38 cents per share, wider than the Zacks Consensus Estimate of a loss of 23 cents and the year-ago loss of 14 cents.
SGEN: 47.87 (+0.53), ABBV: 70.01 (-0.15), ANAC: 149.19 (+0.49), BMY: 65.64 (+1.18)
Small-Cell Lung Cancer - Pipeline Review, H1 2015
M2 - Fri Jul 31, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/szb6j5/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Partial List - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Alchemia Limited - Amgen Inc. - Aposense Ltd. - Array BioPharma Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - BIND Therapeutics, Inc. - Blend Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cantex Pharmaceuticals, Inc. - Celator Pharmaceuticals, Inc. - CellAct Pharma GmbH - Cerulean Pharma, Inc. - Cornerstone Pharmaceuticals, Inc. - Critical Outcome Technologies Inc. - CytRx Corporation - Eisai Co., Ltd. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - ImmunoCellular Therapeutics, Ltd. - Immunomedics, Inc. - Inbiopro Solutions Pvt. Ltd For more information visit http://www.researchandmarkets.com/research/sz...lcell_lung
IMMU: 2.05 (-0.06), CERU: 4.04 (+0.07), AMGN: 176.59 (+4.90), LLY: 84.51 (-0.03), BIND: 4.91 (-0.10), GSK: 43.44 (-0.15), BMY: 65.64 (+1.18), IMUC: 0.48 (unch), AZN: 33.79 (+0.05), CYTR: 2.72 (-0.04), AVEO: 1.41 (+0.03), ABBV: 70.01 (-0.15), EXEL: 5.73 (+0.19), ARRY: 5.81 (+0.06)
Myelodysplastic Syndrome - Pipeline Review, H1 2015 - 72 Companies & 118 Drug Profiles
M2 - Fri Jul 31, 9:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdm2dn/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - 4SC AG - AbbVie Inc. - Acceleron Pharma, Inc. - Actinium Pharmaceuticals, Inc. - Advancell - Agios Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Apogenix GmbH - Aptose Biosciences Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - BioLineRx, Ltd. - Boehringer Ingelheim GmbH - Boryung Pharmaceutical Co., Ltd. - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Celator Pharmaceuticals, Inc. - Celgene Corporation - Celldex Therapeutics, Inc. - Cellerant Therapeutics, Inc. - Celyad - Clevexel Pharma SAS - Concert Pharmaceuticals, Inc. - Constellation Pharmaceuticals, Inc. - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - Cyclacel Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eleos Inc. - Eli Lilly and Company - EpiZyme, Inc. - F. Hoffmann-La Roche Ltd For more information visit http://www.researchandmarkets.com/research/kd...dysplastic
CLDX: 23.55 (+0.03), AMGN: 176.59 (+4.90), EPZM: 22.31 (-0.02), LLY: 84.51 (-0.03), CTIC: 1.85 (unch), BMY: 65.64 (+1.18), CNCE: 16.39 (+0.06), APTO: 4.57 (+0.16), ATNM: 2.26 (+0.10), CYCC: 0.67 (+0.02), BPTH: 1.28 (+0.04), ABBV: 70.01 (-0.15), AGIO: 110.18 (+1.27), CYAD: 55.33 (-0.29), CELGZ: 2.04 (+0.01), XLRN: 28.64 (+0.54), ARRY: 5.81 (+0.06)
Global Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Pipeline Report 2015 - Analysis of 31 Companies & 44 Drug Profiles
M2 - Fri Jul 31, 7:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5m2c5s/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cellular Biomedicine Group, Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - ImmunoGen, Inc. - Immunomedics, Inc. - Infinity Pharmaceuticals, Inc. - Innate Pharma SA - Juno Therapeutics Inc. - Karyopharm Therapeutics, Inc. - Les Laboratoires Servier SAS - LFB S.A. - MedImmune, LLC - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Neopharm Ltd. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Portola Pharmaceuticals, Inc. - Sanofi - SpectraMab GmbH - TG Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. Drug Profiles - 4SC-202 - ACP-196 - afuresertib hydrochloride - AGS-67E - AT-7519 - AZD-6738 - BI-836826 - BMS-986016 - buparlisib hydrochloride - CBM-C19.1 - CBM-C20.1 - CC-122 - Cell Therapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - cerdulatinib - duvelisib - evofosfamide - FBTA-05 - GS-9901 - IMGN-529 - IMMU-114 - IPH-2201 - JCAR-014 - JCAR-015 - MEDI-551 - MOR-208 - moxetumomab pasudotox - nivolumab - obinutuzumab - pilaralisib - S-055746 - selinexor - spebrutinib besylate - TAK-659 - TGR-1202 - tisagenlecleucel-T For more information visit http://www.researchandmarkets.com/research/5m2c5s/refractory
IMMU: 2.05 (-0.06), PTLA: 49.44 (+0.53), IMGN: 18.02 (+0.12), TGTX: 17.45 (+0.39), BMY: 65.64 (+1.18), GSK: 43.44 (-0.15), GILD: 117.86 (-0.04), AZN: 33.79 (+0.05), JUNO: 48.92 (+1.15), INFI: 8.74 (+0.01), ABBV: 70.01 (-0.15), CBMG: 27.95 (+0.87), NVS: 103.75 (+0.57), KPTI: 20.52 (+0.44), CELGZ: 2.04 (+0.01)
Price Isn't a Problem for Gilead Sciences
at The Street - Thu Jul 30, 10:00AM CDT
Drugmaker has one of the best showings of earnings season.
BIIB: 318.78 (+1.78), GILD: 117.86 (-0.04), PFE: 36.06 (+0.33), MRK: 58.96 (+0.44), ABBV: 70.01 (-0.15), CELG: 131.25 (-0.63)
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Jul 30, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA
BIIB: 318.78 (+1.78), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), REGN: 553.66 (+6.56), XOMA: 0.73 (-0.08)
Gilead's Hepatitis C Dominance Unchecked By AbbVie
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 30, 7:04AM CDT
Source: Gilead Sciences via Google Maps. Worries that Gilead Sciences market dominance in treating hepatitis C would falter following the launch of AbbVie 's Viekira Pak this year have been mostly curbed after Gilead Sciences' stellar second...
GILD: 117.86 (-0.04), ABBV: 70.01 (-0.15)
HUMIRA(R) (Adalimumab) Approved by European Commission for Moderate to Severe Hidradenitis Suppurativa (HS)
PR Newswire Europe - Thu Jul 30, 1:00AM CDT
- Decision marks first and only medication approved for adults with hidradenitis suppurativa (HS)
ABBV: 70.01 (-0.15)
Vitae Pharmaceuticals Appoints Dr. John M. Leonard to Board of Directors
GlobeNewswire - Wed Jul 29, 3:30PM CDT
Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of John M. Leonard, M.D., to its board of directors, effective immediately. A 30-year biopharmaceutical industry veteran, Dr. Leonard served as Chief Scientific Officer and Senior Vice President of Research & Development at AbbVie, Inc. following its spin-out from Abbott Laboratories in 2013 until his retirement. While at AbbVie, he led the development of multiple indications of Humira(R), a successful treatment for a variety of autoimmune disorders, as well as a number of other therapeutics.
ABT: 50.69 (-0.08), VTAE: 10.11 (+0.08), ABBV: 70.01 (-0.15)
Gilead Gets Wall Street Love After Q2 Earnings Beat
at Investor's Business Daily - Wed Jul 29, 11:29AM CDT
Big biotech Gilead Sciences (GILD) got a passel of price target increases and jumped more than 5.5% on the stock market Wednesday in the wake of its stellar Q2 report late Tuesday. Analysts noted the strong sales of hepatitis C virus (HCV) drugs and...
GILD: 117.86 (-0.04), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), CELG: 131.25 (-0.63)
Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 29, 10:48AM CDT
Last week saw several major biotech companies like Biogen (BIIB) and AbbVie (ABBV) reporting second quarter results.
BIIB: 318.78 (+1.78), VRTX: 135.00 (-0.46), ALXN: 197.44 (-1.85), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), REGN: 553.66 (+6.56), XOMA: 0.73 (-0.08)
AbbVie (ABBV) Stock Price Target Raised at Deutsche Bank
at The Street - Wed Jul 29, 10:20AM CDT
AbbVie (ABBV) price target was increased to $85 from $80 at Deutsche Bank, while reiterating its 'buy' rating.
ABBV: 70.01 (-0.15)
Gilead (GILD) Beats on Q2 Earnings, Raises 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 8:40AM CDT
Gilead Sciences, Inc.'s (GILD) second-quarter earnings (including stock-based compensation expenses) of $3.10 per share surpassed the Zacks Consensus Estimate of $2.83.
GILD: 117.86 (-0.04), LGND: 108.26 (+0.48), ABBV: 70.01 (-0.15), ANAC: 149.19 (+0.49)
Amgen Stock Clears Buy Point Ahead Of Earnings
at Investor's Business Daily - Tue Jul 28, 1:33PM CDT
A day after Teva Pharmaceuticals (TEVA) broke out of a base, fellow drugmaker Amgen (AMGN) is clearing a buy point. Amgen reports second quarter results after the close on Thursday. Earnings are projected to rise 3%, a slowdown from the first...
AGN: 331.15 (+2.28), BIIB: 318.78 (+1.78), SHPG: 266.81 (+4.29), MYL: 55.99 (-0.36), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), TEVA: 69.02 (-0.05)
The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Merck, Achillion Pharmaceuticals and Express Scripts - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Merck, Achillion Pharmaceuticals and Express Scripts
ESRX: 90.07 (-0.18), GILD: 117.86 (-0.04), ACHN: 8.52 (+0.13), MRK: 58.96 (+0.44), ABBV: 70.01 (-0.15)
Avoid Gilead Shares for Now
at The Street - Tue Jul 28, 7:00AM CDT
Competition and lower earnings cloud its future.
GILD: 117.86 (-0.04), MRK: 58.96 (+0.44), ABBV: 70.01 (-0.15)
Is Gilead Sciences About to Make an Acquisition?
ESTMZ - Mon Jul 27, 2:24PM CDT
Gilead Sciences (GILD) reports its FQ2 ’15 results after the closing bell tomorrow. Both Estimize and Wall Street are predicting a fall in EPS and revenues QoQ. Estimize are forecasting an EPS figure of $2.77 and a revenue target of $7.540B. Wall...
SPY: 210.50 (-0.32), GILD: 117.86 (-0.04), ALXN: 197.44 (-1.85), ABBV: 70.01 (-0.15), NDAQ: 51.03 (+0.04)
4 Stocks to Fight the Virus on World Hepatitis Day - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 12:51PM CDT
Let's turn the spotlight this World Hepatitis Day on some hepatitis-focused companies poised to grow.
ESRX: 90.07 (-0.18), GILD: 117.86 (-0.04), ACHN: 8.52 (+0.13), MRK: 58.96 (+0.44), ABBV: 70.01 (-0.15), BMY: 65.64 (+1.18), NVS: 103.75 (+0.57)
Gilead Can Soothe Biotech Investor Fears with Great 2Q Earnings
at The Street - Mon Jul 27, 11:42AM CDT
Investor confidence in biotech stocks is shaky following last week's Biogen blow-up, making Tuesday's Gilead earnings even more important.
GILD: 117.86 (-0.04), ABBV: 70.01 (-0.15)
3 Signs That the Healthcare Stock Bubble Might Have Just Popped
George Budwell, The Motley Fool - Motley Fool - Mon Jul 27, 9:42AM CDT
Over the past five years or so, healthcare stocks have been absolutely trouncing the broader markets, leading many to call this unprecedented bull run a "bubble." A deeper look, though, reveals that most of this hypergrowth in the healthcare...
BIIB: 318.78 (+1.78), ILMN: 219.30 (+0.43), ABBV: 70.01 (-0.15)
Seattle Genetics (SGEN) Loss Widens in Q2, Ups 2015 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 31, 2:35PM CDT
Seattle Genetics (SGEN) reported a loss of 38 cents per share, wider than the Zacks Consensus Estimate of a loss of 23 cents and the year-ago loss of 14 cents.
SGEN: 47.87 (+0.53), ABBV: 70.01 (-0.15), ANAC: 149.19 (+0.49), BMY: 65.64 (+1.18)
Small-Cell Lung Cancer - Pipeline Review, H1 2015
M2 - Fri Jul 31, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/szb6j5/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Partial List - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Alchemia Limited - Amgen Inc. - Aposense Ltd. - Array BioPharma Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - BIND Therapeutics, Inc. - Blend Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cantex Pharmaceuticals, Inc. - Celator Pharmaceuticals, Inc. - CellAct Pharma GmbH - Cerulean Pharma, Inc. - Cornerstone Pharmaceuticals, Inc. - Critical Outcome Technologies Inc. - CytRx Corporation - Eisai Co., Ltd. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - ImmunoCellular Therapeutics, Ltd. - Immunomedics, Inc. - Inbiopro Solutions Pvt. Ltd For more information visit http://www.researchandmarkets.com/research/sz...lcell_lung
IMMU: 2.05 (-0.06), CERU: 4.04 (+0.07), AMGN: 176.59 (+4.90), LLY: 84.51 (-0.03), BIND: 4.91 (-0.10), GSK: 43.44 (-0.15), BMY: 65.64 (+1.18), IMUC: 0.48 (unch), AZN: 33.79 (+0.05), CYTR: 2.72 (-0.04), AVEO: 1.41 (+0.03), ABBV: 70.01 (-0.15), EXEL: 5.73 (+0.19), ARRY: 5.81 (+0.06)
Myelodysplastic Syndrome - Pipeline Review, H1 2015 - 72 Companies & 118 Drug Profiles
M2 - Fri Jul 31, 9:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdm2dn/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - 4SC AG - AbbVie Inc. - Acceleron Pharma, Inc. - Actinium Pharmaceuticals, Inc. - Advancell - Agios Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Apogenix GmbH - Aptose Biosciences Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - BioLineRx, Ltd. - Boehringer Ingelheim GmbH - Boryung Pharmaceutical Co., Ltd. - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Celator Pharmaceuticals, Inc. - Celgene Corporation - Celldex Therapeutics, Inc. - Cellerant Therapeutics, Inc. - Celyad - Clevexel Pharma SAS - Concert Pharmaceuticals, Inc. - Constellation Pharmaceuticals, Inc. - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - Cyclacel Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eleos Inc. - Eli Lilly and Company - EpiZyme, Inc. - F. Hoffmann-La Roche Ltd For more information visit http://www.researchandmarkets.com/research/kd...dysplastic
CLDX: 23.55 (+0.03), AMGN: 176.59 (+4.90), EPZM: 22.31 (-0.02), LLY: 84.51 (-0.03), CTIC: 1.85 (unch), BMY: 65.64 (+1.18), CNCE: 16.39 (+0.06), APTO: 4.57 (+0.16), ATNM: 2.26 (+0.10), CYCC: 0.67 (+0.02), BPTH: 1.28 (+0.04), ABBV: 70.01 (-0.15), AGIO: 110.18 (+1.27), CYAD: 55.33 (-0.29), CELGZ: 2.04 (+0.01), XLRN: 28.64 (+0.54), ARRY: 5.81 (+0.06)
Global Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Pipeline Report 2015 - Analysis of 31 Companies & 44 Drug Profiles
M2 - Fri Jul 31, 7:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5m2c5s/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cellular Biomedicine Group, Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - ImmunoGen, Inc. - Immunomedics, Inc. - Infinity Pharmaceuticals, Inc. - Innate Pharma SA - Juno Therapeutics Inc. - Karyopharm Therapeutics, Inc. - Les Laboratoires Servier SAS - LFB S.A. - MedImmune, LLC - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Neopharm Ltd. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Portola Pharmaceuticals, Inc. - Sanofi - SpectraMab GmbH - TG Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. Drug Profiles - 4SC-202 - ACP-196 - afuresertib hydrochloride - AGS-67E - AT-7519 - AZD-6738 - BI-836826 - BMS-986016 - buparlisib hydrochloride - CBM-C19.1 - CBM-C20.1 - CC-122 - Cell Therapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - cerdulatinib - duvelisib - evofosfamide - FBTA-05 - GS-9901 - IMGN-529 - IMMU-114 - IPH-2201 - JCAR-014 - JCAR-015 - MEDI-551 - MOR-208 - moxetumomab pasudotox - nivolumab - obinutuzumab - pilaralisib - S-055746 - selinexor - spebrutinib besylate - TAK-659 - TGR-1202 - tisagenlecleucel-T For more information visit http://www.researchandmarkets.com/research/5m2c5s/refractory
IMMU: 2.05 (-0.06), PTLA: 49.44 (+0.53), IMGN: 18.02 (+0.12), TGTX: 17.45 (+0.39), BMY: 65.64 (+1.18), GSK: 43.44 (-0.15), GILD: 117.86 (-0.04), AZN: 33.79 (+0.05), JUNO: 48.92 (+1.15), INFI: 8.74 (+0.01), ABBV: 70.01 (-0.15), CBMG: 27.95 (+0.87), NVS: 103.75 (+0.57), KPTI: 20.52 (+0.44), CELGZ: 2.04 (+0.01)
Price Isn't a Problem for Gilead Sciences
at The Street - Thu Jul 30, 10:00AM CDT
Drugmaker has one of the best showings of earnings season.
BIIB: 318.78 (+1.78), GILD: 117.86 (-0.04), PFE: 36.06 (+0.33), MRK: 58.96 (+0.44), ABBV: 70.01 (-0.15), CELG: 131.25 (-0.63)
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Jul 30, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA
BIIB: 318.78 (+1.78), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), REGN: 553.66 (+6.56), XOMA: 0.73 (-0.08)
Gilead's Hepatitis C Dominance Unchecked By AbbVie
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 30, 7:04AM CDT
Source: Gilead Sciences via Google Maps. Worries that Gilead Sciences market dominance in treating hepatitis C would falter following the launch of AbbVie 's Viekira Pak this year have been mostly curbed after Gilead Sciences' stellar second...
GILD: 117.86 (-0.04), ABBV: 70.01 (-0.15)
HUMIRA(R) (Adalimumab) Approved by European Commission for Moderate to Severe Hidradenitis Suppurativa (HS)
PR Newswire Europe - Thu Jul 30, 1:00AM CDT
- Decision marks first and only medication approved for adults with hidradenitis suppurativa (HS)
ABBV: 70.01 (-0.15)
Vitae Pharmaceuticals Appoints Dr. John M. Leonard to Board of Directors
GlobeNewswire - Wed Jul 29, 3:30PM CDT
Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of John M. Leonard, M.D., to its board of directors, effective immediately. A 30-year biopharmaceutical industry veteran, Dr. Leonard served as Chief Scientific Officer and Senior Vice President of Research & Development at AbbVie, Inc. following its spin-out from Abbott Laboratories in 2013 until his retirement. While at AbbVie, he led the development of multiple indications of Humira(R), a successful treatment for a variety of autoimmune disorders, as well as a number of other therapeutics.
ABT: 50.69 (-0.08), VTAE: 10.11 (+0.08), ABBV: 70.01 (-0.15)
Gilead Gets Wall Street Love After Q2 Earnings Beat
at Investor's Business Daily - Wed Jul 29, 11:29AM CDT
Big biotech Gilead Sciences (GILD) got a passel of price target increases and jumped more than 5.5% on the stock market Wednesday in the wake of its stellar Q2 report late Tuesday. Analysts noted the strong sales of hepatitis C virus (HCV) drugs and...
GILD: 117.86 (-0.04), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), CELG: 131.25 (-0.63)
Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 29, 10:48AM CDT
Last week saw several major biotech companies like Biogen (BIIB) and AbbVie (ABBV) reporting second quarter results.
BIIB: 318.78 (+1.78), VRTX: 135.00 (-0.46), ALXN: 197.44 (-1.85), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), REGN: 553.66 (+6.56), XOMA: 0.73 (-0.08)
AbbVie (ABBV) Stock Price Target Raised at Deutsche Bank
at The Street - Wed Jul 29, 10:20AM CDT
AbbVie (ABBV) price target was increased to $85 from $80 at Deutsche Bank, while reiterating its 'buy' rating.
ABBV: 70.01 (-0.15)
Gilead (GILD) Beats on Q2 Earnings, Raises 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 8:40AM CDT
Gilead Sciences, Inc.'s (GILD) second-quarter earnings (including stock-based compensation expenses) of $3.10 per share surpassed the Zacks Consensus Estimate of $2.83.
GILD: 117.86 (-0.04), LGND: 108.26 (+0.48), ABBV: 70.01 (-0.15), ANAC: 149.19 (+0.49)
Amgen Stock Clears Buy Point Ahead Of Earnings
at Investor's Business Daily - Tue Jul 28, 1:33PM CDT
A day after Teva Pharmaceuticals (TEVA) broke out of a base, fellow drugmaker Amgen (AMGN) is clearing a buy point. Amgen reports second quarter results after the close on Thursday. Earnings are projected to rise 3%, a slowdown from the first...
AGN: 331.15 (+2.28), BIIB: 318.78 (+1.78), SHPG: 266.81 (+4.29), MYL: 55.99 (-0.36), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), TEVA: 69.02 (-0.05)
The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Merck, Achillion Pharmaceuticals and Express Scripts - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Merck, Achillion Pharmaceuticals and Express Scripts
ESRX: 90.07 (-0.18), GILD: 117.86 (-0.04), ACHN: 8.52 (+0.13), MRK: 58.96 (+0.44), ABBV: 70.01 (-0.15)
Avoid Gilead Shares for Now
at The Street - Tue Jul 28, 7:00AM CDT
Competition and lower earnings cloud its future.
GILD: 117.86 (-0.04), MRK: 58.96 (+0.44), ABBV: 70.01 (-0.15)
Is Gilead Sciences About to Make an Acquisition?
ESTMZ - Mon Jul 27, 2:24PM CDT
Gilead Sciences (GILD) reports its FQ2 ’15 results after the closing bell tomorrow. Both Estimize and Wall Street are predicting a fall in EPS and revenues QoQ. Estimize are forecasting an EPS figure of $2.77 and a revenue target of $7.540B. Wall...
SPY: 210.50 (-0.32), GILD: 117.86 (-0.04), ALXN: 197.44 (-1.85), ABBV: 70.01 (-0.15), NDAQ: 51.03 (+0.04)
4 Stocks to Fight the Virus on World Hepatitis Day - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 12:51PM CDT
Let's turn the spotlight this World Hepatitis Day on some hepatitis-focused companies poised to grow.
ESRX: 90.07 (-0.18), GILD: 117.86 (-0.04), ACHN: 8.52 (+0.13), MRK: 58.96 (+0.44), ABBV: 70.01 (-0.15), BMY: 65.64 (+1.18), NVS: 103.75 (+0.57)
Gilead Can Soothe Biotech Investor Fears with Great 2Q Earnings
at The Street - Mon Jul 27, 11:42AM CDT
Investor confidence in biotech stocks is shaky following last week's Biogen blow-up, making Tuesday's Gilead earnings even more important.
GILD: 117.86 (-0.04), ABBV: 70.01 (-0.15)
3 Signs That the Healthcare Stock Bubble Might Have Just Popped
George Budwell, The Motley Fool - Motley Fool - Mon Jul 27, 9:42AM CDT
Over the past five years or so, healthcare stocks have been absolutely trouncing the broader markets, leading many to call this unprecedented bull run a "bubble." A deeper look, though, reveals that most of this hypergrowth in the healthcare...
BIIB: 318.78 (+1.78), ILMN: 219.30 (+0.43), ABBV: 70.01 (-0.15)
(0)
(0)Scroll down for more posts ▼